News Search: More search options


Health: European Nuclear Medicine: Radiopharmaceuticals Market expected worth $1.62 Billion by 2020
 

European Nuclear Medicine/Radiopharmaceuticals Market expected worth $1.62 Billion by 2020


This market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, at a CAGR of 8.2% during the forecast period (2015 to 2020).


[ClickPress, Wed May 17 2017] The report “European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Thyroid, Cardiology) - Forecasts to 2020”, analyzes and studies the major market drivers, restraints, challenges, and opportunities. This report studies the European nuclear medicine/radiopharmaceuticals market for the forecast period of 2015 to 2020. This market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, at a CAGR of 8.2% during the forecast period (2015 to 2020).

Browse 145 market data tables and 60 figures spread through 195 pages and in-depth TOC on “European Nuclear Medicine/Radiopharmaceuticals Market"
http://www.marketsandmarkets.com/Market-Reports/european-nuclear-medicine-radiopharmaceuticals-market-1107.html
Early buyers will receive 10% customization on reports.

The European nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and country.

Based on type, the European nuclear medicine/radiopharmaceuticals market is categorized into diagnostic and therapeutic radioisotopes. In 2015, the diagnostic segment accounts for a major share of the European nuclear medicine/radiopharmaceuticals market. The diagnostic radiopharmaceuticals market is further segmented into SPECT and PET radioisotopes. In 2015, the SPECT segment accounts for the largest share of the European nuclear medicine/radiopharmaceuticals diagnostic market. The therapeutic radiopharmaceuticals market is further segmented into beta emitters, alpha emitters, and brachytherapy. In 2015, the beta emitters segment accounts for the largest share of the European nuclear medicine/radiopharmaceuticals therapeutic market.

Get The PDF Brochure For This Report@
http://www.marketsandmarkets.com/pdfdownload.asp?id=1107

Based on application, the European nuclear medicine/radiopharmaceuticals market is segmented into SPECT, PET, and therapeutic applications. In 2015, the cardiology application accounts for the largest share of European nuclear medicine SPECT market. The PET market is dominated by oncology applications and therapeutic market is dominated by thyroid applications.

On the basis of country, the market is divided into Germany, France, Italy, U.K., Spain, Russia, and the Rest of Europe (RoE). The Rest of Europe comprises Sweden, Switzerland, Poland, Denmark, The Netherlands, and Belgium, among others. In 2015, Germany accounts for the largest share of the European nuclear medicine/radiopharmaceuticals market, followed by France, Italy, and U.K.

Ask For Discount on this report@
http://www.marketsandmarkets.com/discountreports.asp?id=1107
Factors such as increasing preference for SPECT and PET scans, advances in radiotracers, advent of alpha radio immunotherapy-based targeted cancer treatment, increasing incidence & mortality rate of cancer and cardiac ailments are driving the growth of this market. However, factors such as shorter half-life of radiopharmaceuticals, competition from conventional diagnostic procedures are hindering the growth of this market.

Some of the major players in the European nuclear medicine market include Cardinal Health Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).

About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441






Company: Markets and Markets
Contact Name: Mr. Rohan
Contact Email: sales@marketsandmarkets.com
Contact Phone: 1-888-600-6441
Related website
[+] Global news distribution by ClickPress. To manage your News Alerts Subscription, click here. To reach News Alerts subscribers via an Enhanced Distribution, click here.
 

Home | Latest News | Submit News | Advanced Search | About Us | Contact Us | News Alerts Subscribe/Unsubscribe |
Terms and Conditions | Copyright © 2005-2011 ClickPress